Intellia Therapeutics (NTLA) Income towards Parent Company (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Income towards Parent Company for 12 consecutive years, with -$192.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 24.62% year-over-year to -$192.2 million; the TTM figure through Mar 2026 stood at -$625.1 million (up 6.34% YoY), while the FY2025 annual figure was -$1.3 billion, down 4.47% from the prior year.
• Income towards Parent Company eased to -$192.2 million in Q1 2026 per NTLA's latest filing, from -$92.3 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$92.3 million in Q4 2025 and bottomed at -$559.5 million in Q4 2022.
• Historically, Income towards Parent Company has averaged -$201.4 million across 5 years, with a median of -$163.4 million in 2023.
• Annual changes were most pronounced in 2022 — Income towards Parent Company surged 80.49% — and 2025, when it tumbled 97.63%.
• Intellia Therapeutics' Income towards Parent Company stood at -$559.5 million in 2022, then surged by 70.8% to -$163.4 million in 2023, then grew by 22.77% to -$126.2 million in 2024, then increased by 26.86% to -$92.3 million in 2025, then sank by 108.23% to -$192.2 million in 2026.
• Business Quant data shows NTLA's Income towards Parent Company at -$192.2 million in Q1 2026, -$92.3 million in Q4 2025, and -$222.4 million in Q3 2025.